logo.jpg
Processa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare Conference
March 10, 2022 08:30 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, March 10, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...
logo.jpg
Processa Pharmaceuticals Announces Next Generation Capecitabine (Combination of PCS6422 and Capecitabine) Inhibits DPD in Phase 1b Interim Analysis
November 04, 2021 08:15 ET | Processa Pharmaceuticals, Inc.
Next Generation Capecitabine inhibited DPD activity 24-48 hours after PCS6422 administration with < 10% of 5-FU metabolized to FBAL compared to 80% reported for FDA approved capecitabine.24-48...
logo.jpg
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
September 16, 2021 08:30 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...
logo.jpg
Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, August 25-27
August 23, 2021 16:00 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
logo.jpg
Processa Pharmaceuticals to Present at “Zooming with LD Micro” Virtual Investor Event on July 29, 2021 at 12:00 p.m. ET
July 27, 2021 08:30 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, July 27, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it will be presenting at the upcoming “Zooming with LD Micro” virtual investor event...
logo.jpg
Processa Pharmaceuticals to Present at Access to Giving Virtual Conference on July 14, 2021 at 10:30 a.m. ET
July 06, 2021 08:15 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, July 06, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that the company will present at Access to Giving Virtual Conference. The presentation...
logo.jpg
Processa Set to Join Russell Microcap® Index
June 08, 2021 09:15 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, June 08, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
logo.jpg
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
May 26, 2021 09:15 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, May 26, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
logo.jpg
Processa Pharmaceuticals Announces First Patient Dosed in its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
May 20, 2021 16:05 ET | Processa Pharmaceuticals, Inc.
~Processa’s trial is currently enrolling patients with ulcerated Necrobiosis Lipoidica. Detailed information on the trial can be located on clinicaltrials.gov NCT#: 04800562.~ HANOVER, MD., May 20,...
logo.jpg
Processa Pharmaceuticals Schedules Conference Call to Discuss First Quarter Results and Provide Drug Development Update on May 13 at 5:30 p.m. EST
May 07, 2021 08:30 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD., May 07, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...